Day One Announces Updated FIREFLY-1 Data for Tovorafenib and Completion of Rolling NDA Submission to FDA for Relapsed or Progressive Pediatric Low-Grade Glioma (pLGG)
September 11, 2023 08:30 ET
|
Day One Biopharmaceuticals, Inc.
Overall response rate (ORR) greater than 50% across three assessment criteria Median duration of tovorafenib treatment of 15.8 months as of June 5, 2023, with 66% of patients remaining on treatment ...
Day One Announces VRK1 License Agreement and Research Collaboration with Sprint Bioscience
August 16, 2023 08:00 ET
|
Day One Biopharmaceuticals, Inc.
Day One receives an exclusive license to develop and commercialize small molecule drug candidates for pediatric and adult cancers with high unmet need Collaboration augments Day One’s portfolio of...
Day One Reports Second Quarter 2023 Financial Results and Corporate Progress
August 07, 2023 16:30 ET
|
Day One Biopharmaceuticals, Inc.
Results from FIREFLY-1 demonstrate overall response rate (ORR) of 67% and clinical benefit rate (CBR) of 93% in 69 heavily pretreated Response Assessment Neuro-Oncology High-Grade Glioma (RANO-HGG)...
Day One Announces Closing of Public Offering and Full Exercise of the Underwriters’ Option to Purchase Additional Shares
June 12, 2023 08:00 ET
|
Day One Biopharmaceuticals, Inc.
BRISBANE, Calif., June 12, 2023 (GLOBE NEWSWIRE) -- Day One Biopharmaceuticals, Inc. (Nasdaq: DAWN), a clinical-stage biopharmaceutical company dedicated to developing and commercializing targeted...
Day One Announces Pricing of Public Offering of Common Stock
June 06, 2023 22:31 ET
|
Day One Biopharmaceuticals, Inc.
BRISBANE, Calif., June 06, 2023 (GLOBE NEWSWIRE) -- Day One Biopharmaceuticals, Inc. (Nasdaq: DAWN), a clinical-stage biopharmaceutical company dedicated to developing and commercializing targeted...
Day One Announces Proposed Public Offering of Common Stock
June 06, 2023 16:01 ET
|
Day One Biopharmaceuticals, Inc.
SOUTH SAN FRANCISCO, Calif., June 06, 2023 (GLOBE NEWSWIRE) -- Day One Biopharmaceuticals, Inc. (Nasdaq: DAWN), a clinical-stage biopharmaceutical company dedicated to developing and commercializing...
Day One Announces New FIREFLY-1 Data for Tovorafenib (DAY101) and Initiation of Rolling NDA Submission to FDA for Relapsed or Progressive Pediatric Low-Grade Glioma
June 04, 2023 12:45 ET
|
Day One Biopharmaceuticals, Inc.
Overall response rate (ORR) of 67% and clinical benefit rate (CBR) of 93% in 69 heavily pretreated RANO-HGG evaluable patients The Company expects to complete rolling NDA submission in October 2023 ...
Day One to Participate in the Goldman Sachs 44th Annual Healthcare Conference
May 30, 2023 08:00 ET
|
Day One Biopharmaceuticals, Inc.
BRISBANE, Calif., May 30, 2023 (GLOBE NEWSWIRE) -- Day One Biopharmaceuticals (Nasdaq: DAWN), a clinical-stage biopharmaceutical company dedicated to developing and commercializing targeted...
CORRECTION -- Day One Announces Tovorafenib (DAY101) Data and Additional Abstracts to be Presented at the 2023 American Society of Clinical Oncology (ASCO) Annual Meeting
May 25, 2023 20:30 ET
|
Day One Biopharmaceuticals, Inc.
BRISBANE, Calif., May 25, 2023 (GLOBE NEWSWIRE) -- In a release issued under the same headline earlier today by Day One Biopharmaceuticals, Inc. (Nasdaq: DAWN), please note that in the second...
Day One Announces Tovorafenib (DAY101) Data and Additional Abstracts to be Presented at the 2023 American Society of Clinical Oncology (ASCO) Annual Meeting
May 25, 2023 17:00 ET
|
Day One Biopharmaceuticals, Inc.
New clinical data from registrational FIREFLY-1 study to be featured as an oral presentation Conference call and webcast scheduled on Sunday, June 4, 2023 at 6:00 p.m. CT BRISBANE, Calif., May 25,...